2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2284

Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
Abstract Number: 2565

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Abstract Number: 2892

Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
Abstract Number: 791

Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
Abstract Number: 1539

Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
Abstract Number: 1413

Safety of Tocilizumab in Patients Aged <2 Years with Active Systemic Juvenile Idiopathic Arthritis Treated for One Year
Abstract Number: 2191

Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
Abstract Number: 962

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Abstract Number: 2219

Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Abstract Number: 2535

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-506, a Novel, Histone Deacetylase 6 (HDAC6) Inhibitor, in Healthy Volunteers
Abstract Number: 1573

Salivary Dysbiosis Correlates with Clinical Status of Anti-Ro Positive Mothers of Children with Neonatal Lupus
Abstract Number: 1572

Salivary Flow Rates and Oral Health Related Quality of Life Are Associated with Ultrasonographic Scoring of the Major Salivary Glands in Sjogren Syndrome
Abstract Number: 1783

Salivary Gland Disease in IgG4-Related Disease Is Associated with Allergic Histories
Abstract Number: 360

Sarcoidosis Induced By Immune Check Point Inhibitors
Abstract Number: 2539

SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].